SCHEMBL4680752

SCHEMBL4680752

O=C(OCc1ccc(F)cc1F)N1CCNCC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
GRIN2B Q13224 2/20 0.46
BCL9 O00512 1/20 0.46
CTNNB1 P35222 1/20 0.46
PTGDR2 Q9Y5Y4 2/20 0.43
PARP1 P09874 3/20 0.43
IDO1 P14902 2/20 0.43
AGXT P21549 2/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
MAOB P27338 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GSK3B P49841 1/20 0.41
BACE1 P56817 1/20 0.41
MAPT P10636 1/20 0.41
LMNA P02545 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4680744 0.99 ALDH1A1 (0.52) ALDH1A1GRIN2BBCL9CTNNB1PTGDR2
SCHEMBL4678280 0.87 ALDH1A1 (0.47) ALDH1A1GRIN2BHTR2CHTR2BMAPT
SCHEMBL543022 0.87 MEN1 (0.45) ALDH1A1GRIN2BHTR2CHTR2B
SCHEMBL543229 0.87 HTR2C (0.52) ALDH1A1PTGDR2PARP1HTR2CHTR2B
Hydrochloric Acid SCHEMBL4682111 0.86 GRIN2B (0.47) ALDH1A1GRIN2BHTR2CHTR2BMAPT
Hydrochloric Acid SCHEMBL4681782 0.86 MEN1 (0.44) ALDH1A1GRIN2BHTR2CHTR2B
Hydrochloric Acid SCHEMBL4682149 0.86 HTR2C (0.51) ALDH1A1PTGDR2HTR2CHTR2BMAPT
SCHEMBL4678011 0.85 IDO1 (0.48) ALDH1A1IDO1
SCHEMBL4682405 0.85 ENPP2 (0.52) IDO1HTR2CHTR2BLMNARAB9A
SCHEMBL6235265 0.84 MEN1 (0.53) ALDH1A1GRIN2BBCL9CTNNB1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343775-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-06-04 EP disclosed
US-7022707-B2 Piperazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20040235859-A1 Novel piperazine derivatives ADAMS DAVID REGINALD (GB) 2004-11-25 US disclosed
EP-1343775-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-17 EP disclosed
US-20020143020-A1 Novel piperazine derivatives VERNALIS RESEARCH LIMITED (GB) 2002-10-03 US disclosed
WO-2002048124-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143020-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 ALDH1A1 4/4885GRIN2B 668/4885BCL9 3528/4885
US-20040235859-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 ALDH1A1 4/4885GRIN2B 668/4885BCL9 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.